Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
461.57+12.19 (+2.71%)
At close: 4:00PM EST
460.01 -1.56 (-0.34%)
After hours: 6:26PM EST
Loading interactive chart…
- Zacks
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).
- PR Newswire
FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma
Submission supported by data demonstrating Dupixent significantly reduced severe asthma attacks and is the only biologic to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial
- PR Newswire
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma
Single administration of novel antibody cocktail controlled patients' allergic response to cat allergen, preventing early asthma reactions for the duration of the 3-month trial
© 2021 Verizon Media. All rights reserved.
